← All trials
NCT06694935
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2024
- Primary completion
- Jul 31, 2025
- Completion date
- Dec 31, 2025
- First posted
- Nov 19, 2024
- Last posted
- Nov 29, 2024
- Enrollment
- 52
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- 1Globe Biomedical Co., Ltd.Lead sponsor
- 1Globe Biomedical Co., Ltd.Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.